Oligodendroglioma
65
14
19
17
Key Insights
Highlights
Success Rate
61% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.9%
11 terminated out of 65 trials
60.7%
-25.8% vs benchmark
9%
6 trials in Phase 3/4
53%
9 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (65)
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma
Social Determinants of Health in Glioblastoma Population
Study of Olutasidenib and Temozolomide in HGG
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
Investigational Imaging Technique During Brain Surgery
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms